700 related articles for article (PubMed ID: 19962665)
1. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
[TBL] [Abstract][Full Text] [Related]
2. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
3. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
4. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
[TBL] [Abstract][Full Text] [Related]
7. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
8. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
[TBL] [Abstract][Full Text] [Related]
9. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
Geering B; Cutillas PR; Nock G; Gharbi SI; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2007 May; 104(19):7809-14. PubMed ID: 17470792
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
[TBL] [Abstract][Full Text] [Related]
12. BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity.
Chiu YH; Lee JY; Cantley LC
Mol Cell; 2014 Apr; 54(1):193-202. PubMed ID: 24657164
[TBL] [Abstract][Full Text] [Related]
13. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
14. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
15. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.
Ueki K; Algenstaedt P; Mauvais-Jarvis F; Kahn CR
Mol Cell Biol; 2000 Nov; 20(21):8035-46. PubMed ID: 11027274
[TBL] [Abstract][Full Text] [Related]
16. Class IA PI3K regulatory subunits: p110-independent roles and structures.
Fox M; Mott HR; Owen D
Biochem Soc Trans; 2020 Aug; 48(4):1397-1417. PubMed ID: 32677674
[TBL] [Abstract][Full Text] [Related]
17. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
[TBL] [Abstract][Full Text] [Related]
20. Targeting of constitutively active phosphoinositide 3-kinase to GLUT4-containing vesicles in 3T3-L1 adipocytes.
Frevert EU; Bjørbaek C; Venable CL; Keller SR; Kahn BB
J Biol Chem; 1998 Sep; 273(39):25480-7. PubMed ID: 9738018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
